Angiotech Showcases Its Hemostream(TM) Dialysis Catheter At The Society Of Interventional Radiology (SIR) Annual Meeting

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) announced that it will introduce and exhibit its innovative HemoStream(TM) chronic dialysis catheter at the 2008 Society of Interventional Radiology (SIR) Annual Scientific Meeting to be held in Washington, DC from March 15-18, 2008."It's exciting to participate at SIR and showcase the addition of another 'best-in-class' device offered by Angiotech. We also anticipate that the HemoStream(TM) could be a great candidate for our combination drug-device technologies, such as Angiotech's innovative 5-FU anti-infective platform," said George Leondis, General Manager, Angiotech Interventional.
Some of the potential benefits of the HemoStream(TM) catheter include:- Patented Triple Arterial Lumen Design: Ensures functional flow rates in the event that two lumens become completely occluded.- Transition: Provides atraumatic over-the-wire insertion without the need for a peel-away sheath.- 360 degree Arterial Tip Configuration: Eliminates catheter "side- walling" against vessel.
In April 2007, Angiotech entered into an agreement with Rex Medical, LP, which granted Angiotech an exclusive license to market and distribute the HemoStream(TM) catheter worldwide. The U.S. Food and Drug Administration (FDA) has given clearance to begin marketing the HemoStream(TM) chronic dialysis catheter in the United States.

full article >> http://www.medicalnewstoday.com/articles/100588.php